October 26, 2016: While there were definitely positive things in Biogen’s third-quarter report the company also threw in what almost seemed like an afterthought—it was no longer developing amiselimod (MT-1303).
October 26, 2016: As Cempra prepares to meet with the FDA for its anti-bacterial drug Solithera, the company could become the target of a big pharma acquisition. That’s the theory of Kyle Dennis, a trader who follows antibiotic drugmakers.
October 26, 2016: When Novartis shuttered its five-year-old Cell and Gene Therapy Unit in August, it sent shockwaves through the CAR-T community as some believed it to be a signal the company was abandoning the immuno-therapy research program for good.
October 26, 2016: It’s been a tumultuous year or more for MannKind as the company has struggled financially due to multiple rounds of layoffs and poor sales of Afrezza, a rapid-acting inhaled form of insulin to treat diabetes.